← Back to screener

Intellia Therapeutics, Inc. NTLA

Rank #2132 · Nasdaq · $1.7B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
32.7
P/E
-3.6
P/B
1.41
ROE
-38.9%
Op. Margin
-1420.5%
Debt Ratio
26%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Average

P/E -3.6x, P/B 1.41x. Ranks in the top 57% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -38.9%. Ranks in the top 91% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 26%. Ranks in the top 15% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 30.4% year over year. Ranks in the top 95% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2016–$-0.0B$-0.0B$0.0B––
2017–$-0.0B$-0.0B$0.0B–3851
2018$0.0B$-0.0B$-0.0B$-0.0B-195.2-1875
2019$0.0B$-0.1B$-0.1B$0.2B-266.366
2020$0.0B$-0.1B$-0.1B$0.3B-298.611
2021$0.0B$-0.1B$-0.1B$0.3B-246.8143
2022$0.1B$-0.1B$-0.5B$0.3B-235.5380
2023$0.0B$-0.3B$-0.3B$0.5B-810.454
2024$0.1B$-0.5B$-0.5B$1.0B-879.024
2025$0.0B$-0.5B$-0.5B$1.2B-1420.526

← See the full screener